← Back to Screener
Glaukos Corporation (GKOS)
Price$121.62
Favorite Metrics
Price vs S&P 500 (26W)34.16%
Price vs S&P 500 (4W)11.40%
Market Capitalization$7.06B
All Metrics
Book Value / Share (Quarterly)$11.41
P/TBV (Annual)12.61x
Revenue Growth (3Y)21.50%
Cash Flow / Share (Quarterly)$-0.68
Price vs S&P 500 (YTD)4.52%
Gross Margin (TTM)77.97%
Net Profit Margin (TTM)-36.99%
EPS (TTM)$-3.27
10-Day Avg Trading Volume0.66M
EPS Excl Extra (TTM)$-3.27
Revenue Growth (5Y)17.66%
EPS (Annual)$-3.28
ROI (Annual)-25.87%
Gross Margin (Annual)77.97%
Net Profit Margin (5Y Avg)-33.98%
Cash / Share (Quarterly)$4.85
Revenue Growth QoQ (YoY)35.66%
ROA (Last FY)-21.01%
Revenue Growth TTM (YoY)32.33%
EBITD / Share (TTM)$-3.22
ROE (5Y Avg)-20.80%
Operating Margin (TTM)-39.33%
Cash Flow / Share (Annual)$-0.68
P/B Ratio10.77x
P/B Ratio (Quarterly)9.88x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)13.88x
Net Interest Coverage (TTM)-28.92x
ROA (TTM)-19.52%
EV / EBITDA (TTM)2235.19x
EPS Incl Extra (Annual)$-3.28
Current Ratio (Annual)4.69x
Quick Ratio (Quarterly)3.82x
3-Month Avg Trading Volume0.76M
52-Week Price Return30.23%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.94
P/S Ratio (Annual)13.92x
Asset Turnover (Annual)0.57x
52-Week High$130.23
Operating Margin (5Y Avg)-30.48%
EPS Excl Extra (Annual)$-3.28
CapEx CAGR (5Y)28.46%
Tangible BV CAGR (5Y)10.67%
26-Week Price Return38.14%
Quick Ratio (Annual)3.82x
13-Week Price Return9.10%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)4.69x
Enterprise Value$7,040.841
Revenue / Share Growth (5Y)11.90%
Asset Turnover (TTM)0.53x
Book Value / Share Growth (5Y)-5.03%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.84x
Pretax Margin (Annual)-38.04%
Cash / Share (Annual)$4.85
3-Month Return Std Dev53.61%
Gross Margin (5Y Avg)76.48%
Net Income / Employee (TTM)$-0
ROE (Last FY)-28.60%
Net Interest Coverage (Annual)-74.14x
EPS Basic Excl Extra (Annual)$-3.28
P/FCF (TTM)1797.80x
Receivables Turnover (TTM)5.99x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$-3.27
Receivables Turnover (Annual)5.99x
ROI (TTM)-23.25%
P/S Ratio (TTM)13.92x
Pretax Margin (5Y Avg)-34.01%
Revenue / Share (Annual)$8.87
Tangible BV / Share (Annual)$8.94
Price vs S&P 500 (52W)0.40%
Year-to-Date Return7.17%
5-Day Price Return1.30%
EPS Normalized (Annual)$-3.28
ROA (5Y Avg)-13.00%
Net Profit Margin (Annual)-36.99%
Month-to-Date Return12.39%
Cash Flow / Share (TTM)$-1.99
EBITD / Share (Annual)$-3.43
Operating Margin (Annual)-39.33%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-15.28%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.27
P/TBV (Quarterly)12.61x
P/B Ratio (Annual)9.88x
Inventory Turnover (TTM)1.84x
Pretax Margin (TTM)-38.04%
Book Value / Share (Annual)$11.41
Price vs S&P 500 (13W)8.41%
Beta0.76x
P/FCF (Annual)827.11x
Revenue / Share (TTM)$8.82
ROE (TTM)-25.41%
52-Week Low$73.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.18
4.18
4.18
4.18
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
GKOSGlaukos Corporation | 13.92x | 17.66% | 77.97% | -39.33% | $121.62 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Glaukos develops innovative ophthalmic therapies and devices for treating glaucoma, corneal disorders, and retinal diseases. The company commercializes the iStent family of micro-scale glaucoma surgical devices and the novel iDose TR intracameral implant, which delivers continuous glaucoma medication directly inside the eye as an alternative to daily eye drops. It also offers treatment for keratoconus, a rare corneal condition.